Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Long-term Follow-up Study Evaluating the Safety and Efficacy of Subjects With β-thalassemia Treated With Base-edited Autologous Hematopoietic Stem Cell (CS-101) Transplantation

NCT06685536 is registered in ClinicalTrials.gov with CorrectSequence Therapeutics Co., Ltd as lead sponsor.

NCT NCT06685536
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06685536 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Long-term Follow-up Study Evaluating the Safety and Efficacy of Subjects With β-thalassemia Treated With Base-edited Autologous Hematopoietic Stem Cell (CS-101) Transplantation
Lead sponsor
CorrectSequence Therapeutics Co., Ltd
Phase
Observational
Overall status
Enrolling by invitation
Start date
January 18, 2025
Completion date
July 31, 2039
Enrollment
5 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

beta-thalassemia